Postmastectomy Radiation Therapy Reduces Locoregional Recurrence and Disease Recurrence in Triple-Negative Breast Cancer Patients with Stage Ii-Iii Treated with Neoadjuvant Chemotherapy and Mastectomy
X. Chen,L. Zhang,J. Hou,Z. Zhou,X. Wang,Z. Yang,X. Yu,X. Guo,Y. Feng
DOI: https://doi.org/10.1016/j.ijrobp.2015.07.635
2015-01-01
Abstract:To evaluate variables associated with locoregional-recurrence (LRR) and disease recurrence (DR), and to examine the effect of postmastectomy radiation therapy (PMRT) in patients with triple negative breast cancer (TNBC) with stage II-III disease after neoadjuvant chemotherapy (NAC) and modified radical mastectomy (MRM). Between January 1, 2000 and July 31, 2007, a total of 104 female patients with stage II-III TNBC who received NAC and MRM in our institution were identified in the present study. TNBC was based on IHC staining of ER, PR, and HER2. HER2 0-2+ by IHC or HER2 non-amplified by fluorescent in situ hybridization were considered as HER2 negative. The clinical evaluation of the response to NAC was determined by clinical findings according to RECIST. Nighty-three patients (89.4%) received an anthracycline-based regimen. Seventy-nine patients (76%) received PMRT. Patients were divided into two groups for statistical analysis, based on whether they received PMRT or not. These groups were compared in terms of LRR and DR. The median follow-up time was 64 months (range, 12–123 months). Twenty-five patients (24%) developed LRR and 52 patients (50%) developed DR. The 5-year accumulative LRR and DR rate was 26.5% and 49.6%, respectively. Patients in the PMRT group had a statistically more advanced pre-chemotherapy clinical T-stage, clinical AJCC stage and higher proportion of pN+ than patients without PMRT (all P<0.05). Despite their more adverse prognostic features, patients with PMRT had lower 5-year accumulative rate of LRR and DR compared with those without PMRT (LRR, 18.3% vs. 52.2%, P=0.0005; DR, 45% vs. 69.1%, p=0.0334). On the multivariate analysis of the entire study population, no-PMRT and LVI+ were significantly associated with developing LRR (all p<0.05). No-PMRT, LVI+, pathologic LN≥4, and ≥25% positive LN were significantly associated with developing DR (all p<0.05). Analysis for various subsets revealed that, PMRT significantly reduced 5-year LRR rate in patients with pre-chemotherapy clinical stage IIA and IIIA (IIA, 8.3% vs. 46.2%, p=0.019; IIIA, 16% vs. 66.4%, p=0.003). PMRT also significantly reduced 5-year DR rate in patients with pre-chemotherapy clinical stage IIA and >IIIB (IIA, 24.5% vs. 69.3%, p=0.0151; >IIIB, 70.8% vs. 100%, p=0.0481). Despite their significantly worse prognostic features, patients with TNBC treated with NAC and MRM undergo PMRT have a significantly lower LRR and DR rate. The addition of PMRT was associated with decreased LRR and DR rate in the entire cohort as well as in pre-chemotherapy clinical stage IIA patients. Our results may help tailor adjuvant treatment decisions for these specific population. This study is limited due to its small sample size and these findings should be confirmed by a larger, multi-institutional study.